AR126251A1 - Inhibidores de cdk2 - Google Patents
Inhibidores de cdk2Info
- Publication number
- AR126251A1 AR126251A1 ARP220101677A ARP220101677A AR126251A1 AR 126251 A1 AR126251 A1 AR 126251A1 AR P220101677 A ARP220101677 A AR P220101677A AR P220101677 A ARP220101677 A AR P220101677A AR 126251 A1 AR126251 A1 AR 126251A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- cdk2 inhibitors
- acceptable salt
- compound
- useful
- Prior art date
Links
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 title 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente descripción proporciona un compuesto representado por la fórmula estructural (1), o una sal farmacéuticamente aceptable de este útiles para tratar el cáncer. Una composición farmacéutica que comprende un portador farmacéuticamente aceptable y un compuesto de cualquiera de las reivindicaciones 1 - 51, o una sal farmacéuticamente aceptable de este.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163215901P | 2021-06-28 | 2021-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126251A1 true AR126251A1 (es) | 2023-10-04 |
Family
ID=82655170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101677A AR126251A1 (es) | 2021-06-28 | 2022-06-27 | Inhibidores de cdk2 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11932648B2 (es) |
| EP (1) | EP4363423A1 (es) |
| JP (1) | JP2024524373A (es) |
| KR (1) | KR20240046167A (es) |
| CN (1) | CN117897384A (es) |
| AR (1) | AR126251A1 (es) |
| AU (1) | AU2022301047A1 (es) |
| CA (1) | CA3223223A1 (es) |
| CL (1) | CL2023003965A1 (es) |
| CO (1) | CO2024000237A2 (es) |
| CR (1) | CR20230598A (es) |
| DO (1) | DOP2023000280A (es) |
| EC (1) | ECSP24006831A (es) |
| IL (1) | IL309118A (es) |
| MX (1) | MX2024000230A (es) |
| PE (1) | PE20250123A1 (es) |
| TW (1) | TW202317574A (es) |
| UY (1) | UY39832A (es) |
| WO (1) | WO2023278326A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL308314A (en) | 2021-05-07 | 2024-01-01 | Kymera Therapeutics Inc | CDK2 compounds and their uses |
| US11932648B2 (en) | 2021-06-28 | 2024-03-19 | Blueprint Medicines Corporation | CDK2 inhibitors |
| AR131380A1 (es) | 2022-12-16 | 2025-03-12 | Astrazeneca Ab | Purinas 2,6,9-trisustituidas |
| CN120813586A (zh) * | 2023-01-04 | 2025-10-17 | 缆图药品公司 | Cdk2抑制剂 |
| JP2026501700A (ja) * | 2023-01-04 | 2026-01-16 | ブループリント メディシンズ コーポレイション | Ｃｄｋ２阻害剤 |
| WO2024148083A1 (en) * | 2023-01-04 | 2024-07-11 | Blueprint Medicines Corporation | Solid forms of a cdk2 inhibitor |
| JP2026501699A (ja) * | 2023-01-04 | 2026-01-16 | ブループリント メディシンズ コーポレイション | Ｃｄｋ２阻害剤 |
| KR20250152606A (ko) | 2023-02-10 | 2025-10-23 | 블루프린트 메디신즈 코포레이션 | 암 치료용 cdk2 억제제 blu-222 |
| UY40638A (es) | 2023-02-17 | 2024-08-30 | Novartis Ag | Inhibidores de quinasa dependientes de ciclina (cdk2) |
| WO2025188779A1 (en) | 2024-03-04 | 2025-09-12 | Blueprint Medicines Corporation | Cdk2 inhibitors for treatment of cancer |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA12368A (en) | 2000-08-31 | 2004-04-13 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors. |
| WO2002022607A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| MXPA03005609A (es) | 2000-12-21 | 2003-10-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de la proteina cinasa. |
| JP2007517825A (ja) | 2004-01-09 | 2007-07-05 | ノバルティス アクチエンゲゼルシャフト | Ｉｇｆ−ｉｒ阻害剤としてのフェニル−［４−（３−フェニル−１ｈ−ピラゾル−４−イル）−ピリミジン−２−イル］−アミン誘導体 |
| US8362031B2 (en) | 2004-08-20 | 2013-01-29 | University Of Kansas | Lonidamine analogues and treatment of polycystic kidney disease |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| CA2619365A1 (en) | 2005-08-22 | 2007-03-01 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
| DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
| KR20110049217A (ko) | 2009-11-04 | 2011-05-12 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자 |
| KR20120063283A (ko) | 2010-12-07 | 2012-06-15 | 제일약품주식회사 | 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| CA2911856A1 (en) | 2013-05-10 | 2014-11-13 | Karus Therapeutics Ltd | Tri-substituted amino hydroxamate compounds and pharmaceutical compositions thereof for use as histone deacetylase inhibitors |
| JP6612751B2 (ja) | 2013-07-31 | 2019-11-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用 |
| WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
| AU2016272908B2 (en) | 2015-06-04 | 2021-05-06 | Aurigene Oncology Limited | Substituted heterocyclyl derivatives as CDK inhibitors |
| WO2018106667A1 (en) | 2016-12-05 | 2018-06-14 | Microbiotix, Inc. | Broad-spectrum inhibitors of filoviruses |
| WO2019183364A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
| GB201808093D0 (en) | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
| WO2020108516A1 (zh) | 2018-11-27 | 2020-06-04 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
| CN111511738B (zh) * | 2018-11-30 | 2023-01-20 | 江苏豪森药业集团有限公司 | 杂芳类衍生物调节剂、其制备方法和应用 |
| MY210283A (en) | 2019-01-31 | 2025-09-08 | Pfizer | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| US20230102554A1 (en) | 2019-06-28 | 2023-03-30 | Gb002, Inc. | Heterocyclic kinase inhibitors and products and uses thereof |
| BR112022006977A2 (pt) | 2019-10-11 | 2022-09-20 | Incyte Corp | Aminas bicíclicas como inibidores de cdk2 |
| US20230348475A1 (en) | 2020-09-17 | 2023-11-02 | The Translational Genomics Research Institute | Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7 |
| US20240261297A1 (en) | 2021-05-20 | 2024-08-08 | St. John's Cancer Institute | Anti-cdk inhibitors for cancer treatment |
| WO2022266190A1 (en) | 2021-06-16 | 2022-12-22 | Blueprint Medicines Corporation | Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11932648B2 (en) | 2021-06-28 | 2024-03-19 | Blueprint Medicines Corporation | CDK2 inhibitors |
| WO2023092088A1 (en) | 2021-11-19 | 2023-05-25 | Blueprint Medicines Corporation | Cdk2 inhibitors and methods of making and using same |
-
2022
- 2022-06-27 US US17/850,453 patent/US11932648B2/en active Active
- 2022-06-27 CN CN202280057725.7A patent/CN117897384A/zh active Pending
- 2022-06-27 JP JP2023580454A patent/JP2024524373A/ja active Pending
- 2022-06-27 UY UY0001039832A patent/UY39832A/es unknown
- 2022-06-27 CR CR20230598A patent/CR20230598A/es unknown
- 2022-06-27 IL IL309118A patent/IL309118A/en unknown
- 2022-06-27 WO PCT/US2022/035122 patent/WO2023278326A1/en not_active Ceased
- 2022-06-27 TW TW111123974A patent/TW202317574A/zh unknown
- 2022-06-27 EP EP22744613.5A patent/EP4363423A1/en active Pending
- 2022-06-27 CA CA3223223A patent/CA3223223A1/en active Pending
- 2022-06-27 AU AU2022301047A patent/AU2022301047A1/en active Pending
- 2022-06-27 MX MX2024000230A patent/MX2024000230A/es unknown
- 2022-06-27 PE PE2023003487A patent/PE20250123A1/es unknown
- 2022-06-27 AR ARP220101677A patent/AR126251A1/es unknown
- 2022-06-27 KR KR1020247003175A patent/KR20240046167A/ko active Pending
-
2023
- 2023-02-08 US US18/166,178 patent/US11970498B2/en active Active
- 2023-12-18 DO DO2023000280A patent/DOP2023000280A/es unknown
- 2023-12-28 CL CL2023003965A patent/CL2023003965A1/es unknown
-
2024
- 2024-01-12 CO CONC2024/0000237A patent/CO2024000237A2/es unknown
- 2024-01-25 EC ECSENADI20246831A patent/ECSP24006831A/es unknown
- 2024-03-14 US US18/605,248 patent/US20240383902A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202317574A (zh) | 2023-05-01 |
| CO2024000237A2 (es) | 2024-02-05 |
| JP2024524373A (ja) | 2024-07-05 |
| CN117897384A (zh) | 2024-04-16 |
| CL2023003965A1 (es) | 2024-12-06 |
| KR20240046167A (ko) | 2024-04-08 |
| CR20230598A (es) | 2024-04-25 |
| US20230159535A1 (en) | 2023-05-25 |
| AU2022301047A1 (en) | 2024-01-04 |
| ECSP24006831A (es) | 2024-07-31 |
| EP4363423A1 (en) | 2024-05-08 |
| US20240383902A1 (en) | 2024-11-21 |
| PE20250123A1 (es) | 2025-01-16 |
| US20230322791A1 (en) | 2023-10-12 |
| US11932648B2 (en) | 2024-03-19 |
| IL309118A (en) | 2024-02-01 |
| DOP2023000280A (es) | 2024-03-28 |
| CA3223223A1 (en) | 2023-01-05 |
| UY39832A (es) | 2023-01-31 |
| US11970498B2 (en) | 2024-04-30 |
| MX2024000230A (es) | 2024-04-01 |
| WO2023278326A1 (en) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126251A1 (es) | Inhibidores de cdk2 | |
| CO2022010317A2 (es) | Inhibidores de egfr | |
| CO2024001367A2 (es) | Compuestos antivirales | |
| CL2021003202A1 (es) | Compuestos de pirrolidina | |
| CO2021016504A2 (es) | Inhibidores de cdk | |
| ECSP24003566A (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
| CO2021014210A2 (es) | Compuestos de pirrol | |
| CL2024002623A1 (es) | Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2. | |
| MX2024009158A (es) | Inhibidores de parp7. | |
| CL2021003139A1 (es) | Compuestos tricíclicos | |
| UY40220A (es) | Inhibidores de egfr | |
| CO2025016753A2 (es) | Inhibidores de gsk3α y métodos de uso de estos | |
| AR132764A1 (es) | Inhibidores de tyk2 y sus usos | |
| NI200700323A (es) | 4-anilino-3-quinolinocarbonitrilo para el tratamiento de cáncer | |
| UY39662A (es) | Inhibidores de egfr | |
| AR132411A1 (es) | Inhibidores de cdk2 | |
| AR128504A1 (es) | Compuestos antivirales de pirazolopiridinona | |
| AR128894A1 (es) | Inhibidores de kras | |
| CL2025001435A1 (es) | Compuestos inhibidores de ddr1 para tratar cáncer. | |
| AR133642A1 (es) | Inhibidores bicíclicos de dgk | |
| AR133788A1 (es) | Inhibidores de parp7 | |
| DOP2025000167A (es) | Inhibidores de prmt5mta | |
| AR131855A1 (es) | Inhibidores de quinasa dependientes de ciclina (cdk2) |